Study on drug retention in menopausal women with sequential hormone therapy and tibolone

doi:10.5246/jcps.2020.09.060

Journal of Chinese Pharmaceutical Sciences ›› 2020, Vol. 29 ›› Issue (9): 649-655.DOI: 10.5246/jcps.2020.09.060

• Original articles • Previous Articles Next Articles

Study on drug retention in menopausal women with sequential hormone therapy and tibolone

Shurong Shao^1*, Xiaoqing Shao², Yi Chen¹

1. Pharmaceutical department, Ningbo Women and Children’s Hospital, Ningbo 315012, China
2. Anesthesiology Department, the Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, China

Received:2020-05-18 Revised:2020-07-24 Online:2020-09-30 Published:2020-08-19
Contact: Tel.: +86-574-83887054, E-mail: shaoshurong1988@163.com
Supported by:
Ningbo Public Welfare Science and Technology Plan (Grant No. 2019C50089).

Abstract

Abstract:

In the present study, we aimed to retrospectively analyze the medication prescriptions of menopausal women diagnosed with menopausal syndrome in our hospital from 2015 to 2018, and compare the retention rate of estrogen and progesterone sequential therapy and hormone continuous therapy in menopausal women. The rational drug management system of Ningbo Women and Children's hospital was used to screen the prescriptions of menopausal syndrome in 4 years. After the age, year included in the study, and prescription cost were adjusted, Kaplan-Meier regression analysis was performed to compare the prescription retention rates of the two drug regimens. The distribution of the two HRT regimens in the 4 years showed an increasing trend year by year, and the age groups of the two HRT regimens were mainly distributed between 41 and 60 years old, accounting for 97.1% and 87.06%, respectively. The cost distribution for the other two HRT regimens was approximately the same. Compared with the two HRT regimens, the drug retention rate of hormone continuous regimens was higher than that of hormone sequential regimens within 4 years. Kaplan-Meier regression analysis showed that the trend was significant (Tarone-Ware, Chi-square value=3.857, P = 0.050). This study found that the median retention time of HRT therapy in menopausal women in our hospital was about half a year, which was significantly lower than that reported in previous studies of 1 year or longer. In addition, the present study found that compared with Femoston, the tibolone regimen significantly increased retention time in the treatment of menopausal syndrome.

Key words: Hormone replacement therapy, Menopausal syndrome, Femoston, Tibolone, Drug retention rate

CLC Number:

R984

Supporting:

Shurong Shao, Xiaoqing Shao, Yi Chen. Study on drug retention in menopausal women with sequential hormone therapy and tibolone[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(9): 649-655.

References

[1] Brinton, R.D.; Yao, J.; Yin, F.; Mack, W.J.; Cadenas, E. Perimenopause as a neurological transition state. Nat. Rev. Endocrinol. 2015, 11, 393-405.

[2] Martini, J.; Knappe, S.; Garthus-Niegel, S.; Hoyer, J. Mental disorders in women: Natural course during premenstrual phases, peripartum period and perimenopause. Fortschr. Neurol. Psychiatr. 2016, 84, 432-449.

[3] Hansen, K.R.; Craig, L.B.; Zavy, M.T.; Klein, N.A.; Soules, M.R. Ovarian primordial and nongrowing follicle counts according to the Stages of Reproductive Aging Workshop (STRAW) staging system. Menopause. 2012, 19, 164-171.

[4] Soules, M.R.; Sherman, S.; Parrott, E.; Rebar, R.; Santoro, N.; Utian, W.; Woods, N. Executive summary: stages of reproductive aging workshop (STRAW). Climacteric. 2001, 4, 267-272.

[5] Pinkerton, J.V.; Aguirre, F.S.; Blake, J.; Cosman, F.; Hodis, H.N.; Hoffstetter, S.; Kaunitz, M.A.; Kingsberg, S.A.; Maki, P.M.; Manson, J.E.; Marchbanks, P.; Mcclung, M.R.; Nachtigall, L.E.; Nelson, L.M.; Pace, D.T.; Reid, R.L.; Sarrel, P.M. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017, 24, 728-753.

[6] Baber, R.J.; Panay, N.; Fenton, A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016, 19, 109-150.

[7] Fahlén, M.; Fornander, T.; Johansson, H.; Johansson, U.; Rutqvist, L.E.; Wilking, N.; von Schoultz, E. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur. J. Cancer. 2013, 49, 52-59.

[8] Hahn, R.G. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors. Am. J. Obstet. Gynecol. 1989, 161, 1854-1858.

[9] Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995, 273, 199-208.

[10] Chu, K.; Song, Y.; Chatooah, N.D.; Weng, Q.; Ying, Q.; Ma, L.; Qu, F.; Zhou, J. The use and discontinuation of hormone replacement therapy in women in South China. Climacteric. 2018, 21, 47-52.

[11] Liu, Y.; Zhang, Y.; Wang, Q.; Yang, W.; Chen, X.; Jing, S.; Zhao, L.; Zhang, C.; Wei, L.; Li, X.; Feng, W.; Zhong, D.; Fang, Y. Bioequivalence and safety study of letrozole tablet in healthy Chinese postmenopausal women volunteers. J. Chin. Pharm. Sci. 2013, 22, 190-196.

[12] Ettinger, B.; Li, D.K.; Klein, R. Continuation of post-menopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Menopause. 2018, 25, 1187-1190.

[13] Pinkerton, J.V.; Santoro, N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause. 2015, 22, 926-936.

[14] Saeideh, Z.; Raziyeh, M.; Soghrat, F. Comparing the effects of continuous hormone replacement therapy and tibolone on the genital tract of menopausal women; a randomized controlled trial. J. Reprod. Infertil. 2010, 11, 183-187.

[15] Eiken, P.; Kolthoff, N. Compliance with long-term oral hormonal replacement therapy. Maturitas. 1995, 22, 97-103.

Study on drug retention in menopausal women with sequential hormone therapy and tibolone

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles

Metrics

Comments